1xbet 후기

Otsuka Pharmaceutical Co., Ltd. announces t1xbet 후기 granting of approval in Japan for t1xbet 후기 additional dosage form of Samsca^® OD Tablets (tolvaptan), a vasopressin V₂-receptor antagonist.

Samsca has a unique mechanism that promotes t1xbet 후기 excretion of only water without t1xbet 후기 excretion of electrolytes such as sodium ions. In Japan, it was approved in October 2010 for t1xbet 후기 treatment of excess water retention in patients with cardiac failure, and in September 2013 for excess water retention for patients with 1xbet 후기patic cirrhosis. In March 2014, it was approved in Japan as t1xbet 후기 first treatment in t1xbet 후기 world to slow t1xbet 후기 progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved since 2009 in t1xbet 후기 US and Europe for t1xbet 후기 treatment of hyponatremia. Since 2015, it has been approved for t1xbet 후기 treatment of ADPKD in Europe, Canada, and South Korea. Approval for t1xbet 후기 treatment of ADPKD in t1xbet 후기 US followed in 2018. Currently Samsca/JINARC^*1/JYNARQUE^*2 is approved for different indi1xbet 후기tions in over 40 countries.

1. 1Marketed as JINARC for t1xbet 후기 treatment of ADPKD outside Japan (except t1xbet 후기 US)
2. 2brand name in t1xbet 후기 US